AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

Source: 
CP Wire
snippet: 

AbbVie (NYSE: ABBV), announced on 5/1/18 that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.